Skip to Content

Invokana (canagliflozin) Disease Interactions

There are 4 disease interactions with Invokana (canagliflozin):

Major

SGLT-2 inhibitors (Includes Invokana) ↔ renal dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The glucose lowering effects of SGLT-2 inhibitors is decreased in patients with worsening renal function. Additionally, SGLT-2 inhibitors increase serum creatinine and decrease eGFR. The elderly and patients with moderate renal impairment are at increased risk of further renal dysfunction. Renal function should be evaluated before treatment initiation and monitored regularly in these patients. The use of SGLT-2 inhibitors in patients with severe renal impairment, end stage renal dysfunction (ESRD), or undergoing dialysis is contraindicated. Based on its mechanism of action, SGLT-2 inhibitors are not expected to be effective in patients with this level of renal dysfunction.

Moderate

Canagliflozin (Includes Invokana) ↔ hyperkalemia

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Hyperkalemia

Canagliflozin can cause hyperkalemia and it should be used with caution in patients predisposed to this condition due to the use of certain medications or other medical conditions. Serum potassium levels should be monitored periodically after initiating canagliflozin, specially in patients with impaired renal function.

Moderate

SGLT-2 inhibitors (Includes Invokana) ↔ hyperlipidemia

Moderate Potential Hazard, Moderate plausibility. Applies to: Hyperlipidemia

There have been reports of dose-related increases in LDL cholesterol with the use of SGLT-2 inhibitors. Cholesterol levels should be monitored before and during treatment and appropriate therapy should be initiated if needed.

Moderate

SGLT-2 inhibitors (Includes Invokana) ↔ Hypotension

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Hypotension

SGLT-2 inhibitors cause intravascular volume contraction and symptomatic hypotension may occur after treatment initiation especially in the elderly, in patients with impaired renal function, low systolic blood pressure, or using diuretics . Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.

Invokana (canagliflozin) drug interactions

There are 345 drug interactions with Invokana (canagliflozin)

Invokana (canagliflozin) alcohol/food interactions

There are 2 alcohol/food interactions with Invokana (canagliflozin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide